Immune reconstitution and clinical outcomes in B-ALL patients with versus without pre-HSCT Immunotherapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Immune Recovery and Clinical Outcomes After HSCT in B-ALL Patients With or Without Prior Immunotherapy

  • By

  • Yu-Yuan Zeng

  • Guan-Hua Hu

  • Ying-Xi Zuo

  • Pan Suo

  • Lu Bai

  • Feng Zhang

  • Hui-Fang Wang

  • Ying-Jun Chang

  • Meng Lv

  • Xiao-Hui Zhang

  • Yu Wang

  • Lan-Ping Xu

  • Xiao-Jun Huang

  • Lin Wang

  • Yi-Fei Cheng

  • October 21, 2026

Share

  • 1

    This retrospective study compared immune reconstitution after HSCT in children with B-ALL who received chemotherapy alone or immunotherapy before transplantation.

  • 2

    Among 312 first-HSCT recipients, 168 received pre-HSCT immunotherapy and 144 received chemotherapy alone; longitudinal immune analyses included 305 patients.

  • 3

    T-cell and B-cell counts generally increased after HSCT, but recovery was incomplete: CD4+ T-cell counts and the CD4/CD8 ratio remained below age-expected levels at 24 months.

  • 4

    Compared with immunotherapy, chemotherapy was associated with higher levels of several CD4+ T-cell subsets and CD28+ T cells at selected post-HSCT time points.

  • 5

    B-cell counts and IgG and IgM concentrations followed similar recovery trajectories between groups, whereas IgA levels and several T-cell subsets differed over time.

Original Source(s)

Immune reconstitution and clinical outcomes in B-ALL patients with versus without pre-HSCT Immunotherapy

  • by Yu-Yuan Zeng, Guan-Hua Hu, Ying-Xi Zuo, Pan Suo, Lu Bai, Feng Zhang, Hui-Fang Wang, Ying-Jun Chang, Meng Lv, Xiao-Hui Zhang, Yu Wang, Lan-Ping Xu, Xiao-Jun Huang, Lin Wang, Yi-Fei Cheng

  • October 21, 2026

Related Content

Cancer Treatment During Pregnancy and Maternal and Infant Outcomes: A Descriptive Cohort Study Using a Japanese Claims Database

Diagnostic performance and pathologic associations of the UroVysion assay in patients with upper tract lesions and negative urinary cytology: a large-scale real-world study of 1,256 patients

2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.

  • October 15, 2026

  • 1 min